The scientific goals of the Experimental and Developmental (EDT) Program are to: 1) Discover and validate novel therapeutic targets;2) Identify new therapeutic agents and approaches, and 3) Conduct early phase translational clinical trials of novel therapies. The EDT Program is comprised of 25 members from two schools at the University of Texas Health Science Center at San Antonio (UTHSCSA) and one college at the University of Texas at San Antonio (UTSA). The EDT membership represents 11 departments and has been recruited from notable institutions including Harvard Medical School, MD Anderson Cancer Center and UT Southwestern. The EDT Program members have a wide range of expertise, from synthetic organic chemistry and structural biology, through lead identification and IND-enabling studies, obtaining an IND, to conducting clinical trials. These complementary areas of expertise provide the opportunities for cutting-edge translational research. Seven Program members are clinician scientists, physicians, or dentists who provide a strong translational focus to the program. The Co-Leaders, Drs. Weitman and Mooberry have complementary areas of expertise and interests to span the entire range of activities of the Program. In the past budget year, EDT members received a total of $2,150,045 of NCI funding (11 grants) and an additional $2,723,945 (15 grants) of other peer-reviewed cancer-related grant support. The EDT Program has 177 peer-reviewed cancer related publications of which 89 (50%) are intra-programmatic collaborations and 26 (15%) are inter-programmatic collaborations.
The Experimental and Developmental Therapeutics (EDT) Program takes the lead in the Cancer Therapy & Research Center's effort to develop and test new treatments for cancer. It is an integrated multidisciplinary collaborative effort between diverse disciplines of pre-clinical and clinical scientists, all of whom are focused on improving the treatment of cancer.
|Meng, Jia; Lu, Zhiliang; Liu, Hui et al. (2014) A protocol for RNA methylation differential analysis with MeRIP-Seq data and exomePeak R/Bioconductor package. Methods 69:274-81|
|Ghosh, Sagar; Hughes, Daniel; Parma, Dorothy Long et al. (2014) Association of obesity and circulating adipose stromal cells among breast cancer survivors. Mol Biol Rep 41:2907-16|
|Gong, Jingjing; Muñoz, Amanda R; Chan, Daniel et al. (2014) STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncotarget 5:2529-41|
|Fok, Wilson C; Livi, Carolina; Bokov, Alex et al. (2014) Short-term rapamycin treatment in mice has few effects on the transcriptome of white adipose tissue compared to dietary restriction. Mech Ageing Dev 140:23-9|
|Morales, Liza D; Casillas Pavón, Edgar A; Shin, Jun Wan et al. (2014) Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling. PLoS One 9:e97104|
|Mousavi, Seyed Mohsen; Sundquist, Jan; Hemminki, Kari (2014) Risk of Kaposi sarcoma among immigrants to Sweden. Acta Derm Venereol 94:476-7|
|Ankerst, Donna P; Boeck, Andreas; Freedland, Stephen J et al. (2014) Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 32:185-91|
|Biswas, Tanuka; Gu, Xiang; Yang, Junhua et al. (2014) Attenuation of TGF-* signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett 346:129-38|
|Ramirez, Amelie G; Munoz, Edgar; Holden, Alan E C et al. (2014) Incidence of hepatocellular carcinoma in Texas Latinos, 1995-2010: an update. PLoS One 9:e99365|
|Bansal, H; Yihua, Q; Iyer, S P et al. (2014) WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia 28:1171-4|
Showing the most recent 10 out of 616 publications